Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report

MeSH terms

• Adult
• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / therapeutic use
• Bortezomib / administration & dosage
• Bortezomib / therapeutic use
• Chronic Disease
• Disease Management
• Female
• Graft vs Host Disease / diagnosis
• Graft vs Host Disease / etiology*
• Graft vs Host Disease / therapy*
• Hematopoietic Stem Cell Transplantation / adverse effects*
• Humans
• Immunologic Factors / administration & dosage
• Immunologic Factors / therapeutic use
• Immunomodulation / drug effects
• Multiple Myeloma / complications*
• Multiple Myeloma / diagnosis
• Multiple Myeloma / therapy
• Transplantation, Homologous
• Treatment Outcome